Pharma


  • the FDA Headquarters
    Image attribution tooltip
    Sara Silbiger via Getty Images
    Image attribution tooltip

    Humira biosimilar from Alvotech, Teva wins FDA approval on third attempt

    The companies didn’t reveal their planned price for Simlandi, which will be the 10th Humira copycat to reach the U.S. market.

    By Feb. 26, 2024
  • Lab worker holding equipment.
    Image attribution tooltip
    Permission granted by PHC Corporation of North America
    Image attribution tooltip
    Sponsored by PHC Corporation of North America

    Choosing laboratory equipment with workplace experience in mind

    Making equipment choices with employee experience in mind can help researchers build top-performing teams while enhancing operational efficiencies.

    Feb. 26, 2024
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip
    Trendline

    Top 5 stories from BioPharma Dive

    A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?

    By BioPharma Dive staff
  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images
    Image attribution tooltip

    J&J secures EMA backing for earlier CAR-T use in multiple myeloma

    European drug regulators recommended clearing J&J and Legend Biotech's Carvykti for use as early as after first relapse, potentially giving the therapy an advantage over Bristol Myers’ Abecma.

    By Feb. 23, 2024
  • Pharmaceutical Executives Testify At Senate Finance Committee Hearing On Drug Prices
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Outgoing AbbVie CEO leaves a divisive Humira legacy and lasting impact on pharma

    Richard Gonzalez led AbbVie to become one of the largest pharmaceutical firms, but the company's pricing and patent tactics brought criticism, too.

    By Michael Gibney • Feb. 22, 2024
  • Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Rick Gonzalez, longtime AbbVie CEO, to step down in July

    The veteran executive, who guided AbbVie through its separation from Abbott Laboratories, will be succeeded by Chief Operating Officer Robert Michael. 

    By Feb. 20, 2024
  • mirror laptop image showing image of client portal with blue background
    Image attribution tooltip
    Permission granted by ClinicalMind
    Image attribution tooltip
    Sponsored by ClinicalMind

    Here are 7 practical ways asynchronous advisory programs can make an impact in 2024

    Can asynchronous advisory programs can add distinct value to your strategic mix? Yes! Here's how.

    Feb. 20, 2024
  • A photo of a building with the Astellas Pharma logo.
    Image attribution tooltip
    Courtesy of Astellas Pharma
    Image attribution tooltip

    Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies

    Kelonia will receive $40 million upfront through the partnership, and could receive $35 million more if Astellas opts into another program.

    By Feb. 16, 2024
  • Three people in suits sit on a dias at a Congressional hearing.
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts

    Forced into testifying by Senate HELP chair Bernie Sanders, the heads of Bristol Myers Squibb, J&J and Merck largely avoided major missteps.

    By Feb. 8, 2024
  • Large letters spelling Amgen are seen next to a stone wall
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Obesity drug mania takes over Amgen’s earnings call

    Analysts pressed company executives Tuesday on the potential of its GLP-1 drug for weight loss, early-stage results for which were published this week.

    By Feb. 7, 2024
  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca to invest $300M in US cell therapy plant

    The UK drugmaker is adding a facility in Rockville, Maryland, after a spate of dealmaking in the therapeutic field.

    By Kristin Jensen • Feb. 7, 2024
  • An Eli Lilly logo is seen at the top of a building.
    Image attribution tooltip
    JHVEPhoto via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly sales surge on obesity, diabetes drug demand

    The company also reported trial results suggesting tirzepatide, the drug Lilly now sells as Mounjaro and Zepbound, could treat a common liver disease.

    By Feb. 6, 2024
  • Johnson & Johnson's new logo is seen on an office lobby wall.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J says top drug prospect works across autoimmune disorders

    The pharma disclosed positive results from two studies testing its antibody drug nipocalimab in generalized myasthenia gravis or Sjögren's disease.

    By Feb. 5, 2024
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi appoints Nestlé executive as new finance chief

    François-Xavier Roger will replace current CFO Jean-Baptiste Chasseloup de Chatillon as Sanofi continues a research pivot and cost-cutting drive.

    By Feb. 1, 2024
  • Merck sign
    Image attribution tooltip
    Marko Georgiev / Stringer via Getty Images
    Image attribution tooltip

    Merck keeps deal focus with Keytruda patent cliff on horizon

    The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.

    By Feb. 1, 2024
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche shuffles early stage pipeline as it joins obesity rush

    Roche said it was shelving those drugs in favor of experimental programs to treat obesity that it gained from its takeover of Carmot Therapeutics.

    By Feb. 1, 2024
  • Image attribution tooltip
    Warren Little via Getty Images
    Image attribution tooltip

    GSK sales of RSV vaccine stay strong, beating forecast

    The British drugmaker reported Arexvy sales of about $1.5 billion for 2023, higher than the range it had previously predicted for the year. 

    By Jan. 31, 2024
  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip

    Novo resumes supplying starter doses of obesity drug Wegovy

    The announcement ends a nine-month delay related to manufacturing snags that slowed Novo’s ability to meet demand for the fast-selling medicine.

    By Jan. 31, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers gets positive data in subcutaneous Opdivo trial

    An under-the-skin Opdivo shot produced similar results to an intravenous formulation in kidney cancer, giving Bristol Myers a chance at sustaining sales past a key patent expiration in 2028.

    By Jan. 29, 2024
  • J&J CEO Joaquin Duato
    Image attribution tooltip
    Mike Coppola via Getty Images
    Image attribution tooltip

    J&J focuses on newer meds to offset Stelara patent cliff

    Executives talked up the company’s cash position and incremental dealmaking as ways to buttress against incoming competition.

    By Michael Gibney • Jan. 24, 2024
  • A medical Illustration showing lung cancer or bronchial carcinoma.
    Image attribution tooltip
    Mohammed Haneefa Nizamudeen via Getty Images
    Image attribution tooltip

    Gilead ADC medicine misses goal in closely watched lung cancer study

    Trodelvy didn’t outperform chemotherapy in a large study of people with a common lung tumor, a setback that sent company shares down by double digits.

    By Jan. 22, 2024
  • U.S. capitol building with stormy skies
    Image attribution tooltip
    Douglas Rissing via Getty Images
    Image attribution tooltip

    Sanders threatens to subpoena J&J, Merck CEOs over drug prices

    The Senate HELP committee, which is seeking testimony from J&J's Joaquin Duato and Merck's Robert Davis, hasn't issued a subpoena since 1981.

    By Jan. 19, 2024
  • Chris Arendt
    Image attribution tooltip
    Permission granted by Takeda Pharmaceuticals
    Image attribution tooltip

    Five years after Shire deal, Takeda hopes to reap rewards of latest reinvention

    Amid scrutiny of Takeda’s past megamerger, Chief Scientific Officer Chris Arendt said it has built a drug pipeline that will deliver.

    By Meagan Parrish • Jan. 19, 2024
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    Bayer signals ‘significant’ layoffs in plan to shrink bureaucracy

    The company said it has secured agreement from labor representatives in Germany for job cuts that will shed “many managerial employees.”

    By Kristin Jensen • Jan. 18, 2024
  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    FDA widens approval of Vertex’s CRISPR medicine to treat beta thalassemia

    The agency’s decision to expand use of Casgevy, which won a landmark OK for sickle cell disease in December, comes two months ahead of schedule.

    By Jan. 16, 2024
  • Two hands working on a modern laptop
    Image attribution tooltip
    Permission granted by ClinicalMind
    Image attribution tooltip
    Sponsored by ClinicalMind

    Simplifying speaker engagement in Pharma: A holistic approach

    Relationships with Speaker Bureau faculty are among the most important that a biopharmaceutical company nurtures.

    Jan. 16, 2024